RDInvesting Provides Investors with Free In-Depth Equity Reports on MR, PFPT, STX and TRSadmin
Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
Mindray Medical International Ltd. (NYSE: MR) shares gained 4.18 percent to close at $37.10 a share Friday. The stock traded between $35.01 and $38.68 on volume of 8.0 million shares traded. Analysts at Bank of America Merrill Lynch have recently initiated coverage on the company with a “buy” rating. Shares of Mindray Medical have gained approximately 13.0 percent year-to-date.
Find out more about Mindray Medical including full access to the free equity report at:
Proofpoint Inc. (NASDAQ: PFPT) shares increased 4.16 percent to close at $29.27 a share Friday. The stock traded between $28.15 and $29.66 on volume of 450,619 shares traded. Analysts at FBR Capital have recently initiated coverage on the company with an “outperform” rating. Shares of Proofpoint have gained approximately 135.0 percent year-to-date.
Find out more about Proofpoint including full access to the free equity report at:
Seagate Technology PLC (NASDAQ: STX) shares gained 1.19 percent to close at $50.00 a share Friday. The stock traded between $49.45 and $50.84 on volume of 2.71 million shares traded. Analysts at Citi have recently initiated coverage on the company with a “buy” rating. Shares of Seagate Technology have gained approximately 64.0 percent year-to-date.
Find out more about Seagate Technology including full access to the free equity report at:
TriMas Corp. (NASDAQ: TRS) shares gained 2.82 percent to close at $36.81 a share Friday. The stock traded between $35.55 and $36.94 on volume of 453,329 shares traded. Analysts at Sidoti have recently upgraded the company’s rating to “buy” from “neutral”. Shares of TriMas have gained approximately 30.0 percent year-to-date.
Find out more about TriMas including full access to the free equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Research Driven Investing
Posted: December 16th, 2013 under ACCESSWIRE.